The past decade has been defined by extraordinary progress in cell and gene therapy. 

Scientific breakthroughs that once seemed impossible have become reality. New therapies are reaching patients, clinical pipelines continue to grow, and investment across the sector remains significant. As an industry, we have demonstrated what advanced therapies can achieve. 

The question is no longer whether these therapies work. 

The question is whether we can deliver them consistently, efficiently, and at scale. 

Cell and gene therapy is entering a new phase of maturity. Success is creating a different set of challenges, and increasingly those challenges are operational rather than scientific. 

The next chapter of industry growth will be defined by organisations that can translate innovation into reliable delivery. 

From Innovation Challenge to Delivery Challenge 

In the early years of cell and gene therapy, the primary goal was proving clinical potential. 

Today, many organisations face a different reality. 

They must successfully manage: 

• Larger patient populations 

• Expanding treatment networks 

• More complex stakeholder ecosystems 

• Increasing regulatory expectations 

• Greater pressure on cost and efficiency 

• Commercial-scale operations 

These are positive challenges because they reflect industry progress. 

However, they also expose limitations in processes, systems, and operating models that were originally designed for a smaller scale of activity. 

As therapies expand beyond early adoption and into broader commercial use, operational scalability becomes critical. 

What Is Operational Scalability in Cell and Gene Therapy? 

Operational scalability is an organisation’s ability to increase therapy volume, complexity, and geographic reach without introducing unacceptable levels of risk, cost, or inefficiency. 

In practice, this means being able to coordinate: 

• Treatment centres 

• Manufacturing teams 

• Logistics providers 

• Patient support services 

• Regulatory requirements 

• Data management processes 

While maintaining visibility and control throughout the therapy journey. 

For many organisations, this is becoming one of the defining challenges of the next decade. 

The Industry Cannot Scale Through Manual Coordination Alone 

One of the most common themes emerging across the sector is growing operational complexity. 

The delivery of advanced therapies depends on multiple stakeholders working together across highly regulated environments. Every handoff, every data exchange, and every decision can influence outcomes. 

Yet many organisations still rely on disconnected systems, fragmented workflows, manual processes, and multiple technology platforms that were never designed to operate as a unified ecosystem. 

As therapy volumes increase, these challenges become harder to manage. 

Manual coordination can support innovation for a period of time. 

It cannot sustainably support scale. 

This is not a technology problem alone. 

It is an operational design problem. 

The Five Operational Priorities for the Next Phase of CGT 

As the industry evolves, I believe five priorities will determine which organisations are best positioned to scale successfully. 

1. Standardisation 

The industry has benefited enormously from innovation and flexibility. 

However, growth requires greater consistency. 

Common approaches to onboarding, data management, reporting, and operational execution can reduce friction across the ecosystem while improving efficiency and compliance. 

2. Data Visibility 

Organisations cannot effectively manage what they cannot see. 

Leaders need greater visibility across therapy journeys, operational performance, bottlenecks, and emerging risks. 

Real-time information enables better decisions. 

3. Site Enablement 

Expanding patient access will depend heavily on the ability to support treatment centres effectively. 

Sites should not become operational bottlenecks. 

Reducing complexity at the point of care will be essential. 

4. Ecosystem Collaboration 

No organisation operates in isolation. 

Manufacturers, therapy developers, treatment centres, logistics providers, technology partners, and standards bodies all play critical roles in successful delivery. 

The organisations that collaborate effectively will create stronger outcomes for everyone involved. 

5. Operational Orchestration 

Perhaps most importantly, the industry must move beyond simply automating individual processes. 

The future lies in orchestration. 

Organisations need the ability to connect systems, people, data, and workflows across complex therapy ecosystems while maintaining control, visibility, and compliance. 

Why Technology Must Evolve 

Technology remains a critical enabler of growth. 

However, expectations are changing. 

Historically, many organisations focused on digitising specific activities or eliminating isolated manual tasks. 

Today’s challenge is broader. 

Technology must support coordination across the entire therapy journey. 

It must simplify complexity rather than add to it. 

It must enable collaboration rather than create silos. 

Most importantly, it must support the operational maturity required for long-term scalability. 

AI Will Be Part of the Solution, But Not the Entire Solution 

Artificial intelligence is understandably generating significant interest across life sciences and healthcare, and cell and gene therapy is no exception. 

There is genuine potential for AI to help organisations improve forecasting, identify operational bottlenecks, support decision-making, surface insights from complex data sets and reduce administrative burden. 

These opportunities are exciting, and as an industry we should continue to explore them. 

However, I believe it is important that we approach AI with a degree of pragmatism. 

In highly regulated, patient-critical environments, trust, transparency, governance and data quality matter just as much as innovation. AI is unlikely to solve operational challenges on its own. In many cases, organisations must first address foundational issues such as data visibility, process standardisation and system connectivity before they can fully realise AI’s potential. 

At TrakCel, we are actively exploring where AI can deliver meaningful value across advanced therapy operations, but we do so with a clear focus on patient safety, regulatory compliance and practical outcomes. 

The greatest opportunity may not be replacing human expertise, but augmenting it. Helping teams make better decisions, respond more quickly to emerging risks, and operate with greater confidence as therapies continue to scale. 

Ultimately, AI should support operational excellence, not be a substitute for it. 

Why Collaboration Matters More Than Ever 

One lesson continues to emerge across every conversation we have with industry leaders. 

No single stakeholder can solve these challenges alone. 

The future of advanced therapy operations will be shaped through collaboration between manufacturers, treatment centres, technology providers, regulators, logistics organisations, and standards bodies. 

This is precisely why initiatives such as Industry Advancement Boards remain so valuable. 

They provide opportunities to discuss practical challenges openly, share lessons learned, and collectively develop approaches that help the entire sector move forward. 

As the industry grows, collaboration becomes increasingly important. 

Not because it is desirable. 

Because it is necessary. 

Frequently Asked Questions 

What is the biggest challenge facing cell and gene therapy today? 

Increasingly, the challenge is operational delivery rather than scientific innovation. As therapies scale, organisations must manage growing complexity across treatment centres, manufacturing, logistics, data management, and patient support services. 

Why is operational orchestration important in advanced therapies? 

Operational orchestration helps coordinate stakeholders, systems, workflows, and data across complex therapy journeys. It improves visibility, reduces risk, and supports scalability. 

Can cell and gene therapy scale without greater standardisation? 

Standardisation will play an increasingly important role in supporting industry growth. While innovation remains essential, common data models, operational approaches, and onboarding processes can help reduce friction and improve efficiency across the ecosystem. 

Looking Ahead 

I remain incredibly optimistic about the future of cell and gene therapy. 

The innovation pipeline remains strong. New therapeutic possibilities continue to emerge. Patient outcomes will continue to improve. 

But the organisations that lead the next phase of growth may not necessarily be those with the most innovative science. 

They may be the organisations that are best able to deliver that science consistently, efficiently, and at scale. 

The industry has already proven what these therapies can do. 

The challenge now is building the operational foundations that allow them to reach every patient who needs them. 

And I believe that challenge represents one of the most exciting opportunities facing our sector today.